Cargando…
PD-L1 immune suppression in cancer: Tumor cells or host cells?
Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Th...
Autores principales: | Kleinovink, Jan Willem, van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543902/ https://www.ncbi.nlm.nih.gov/pubmed/28811961 http://dx.doi.org/10.1080/2162402X.2017.1325982 |
Ejemplares similares
-
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017) -
Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013) -
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
por: Fransen, Marieke F., et al.
Publicado: (2021) -
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer
por: Schalper, Kurt A
Publicado: (2014) -
Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)